Kymera Therapeutics completed enrollment in its KT-621 Phase 2b trial for atopic dermatitis six months early, moving the expected data readout to year-end 2026 and planning Phase 3 trials by mid-2027. The company also continues trials for asthma and other programs, with strong financials including $1.5 billion in cash to fund operations into 2029. These advances highlight Kymera's progress in developing oral therapies for immunological diseases, aiming to address significant treatment gaps. Upcoming data releases and trial initiations position Kymera for growth and potential new treatment options for patients.
Circle has introduced a new borrowing service for institutional clients that allows them to use Bitcoin as collateral to borrow USDC without selling their BTC holdings. The service operates on the Arc and Ethereum networks through Circle Mint account...
An Ethereum ICO-era whale purchased 8,492.8 ETH worth $23.7 million at an average price of $2,794 on September 21, marking a return to the market after six months. This buying helped push Ethereum's price above $2,800 for the first time since January...
Dutch police arrested two men suspected of using counterfeit EURC stablecoins to fraudulently obtain Rolex watches from sellers on Marktplaats, a major Dutch online marketplace. The fake tokens appeared genuine in wallets, tricking sellers into relea...
Agree Realty Corporation maintains a robust portfolio of 2,824 retail properties and strong credit metrics, including a low secured debt ratio and high asset coverage. Its common stock trades at a 1.34x price-to-book with a 5.21% AFFO yield, supporti...
Ethereum (ETH) has surged past the $2,700 mark, trading at $2,716.86 after a 5.7% gain in 24 hours, marking its strongest third-quarter performance since 2016 with a 67.57% gain in Q3 2026. This rally occurs despite regulatory setbacks and a Fed rate...
